INTERNATIONAL FLAVORS & FRAGRANCES INC (IFF): what the price assumes

In the published model solve dated 2026-Q2, anchored at $87.95, INTERNATIONAL FLAVORS & FRAGRANCES INC (IFF) is priced for today's economics sustained for ~5.8 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/IFF

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.3% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: elevated (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.5%); the inversion above states its own rate.

Per-Model Detail (n=11)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• IFF is a flavors, fragrances, and specialty-ingredients maker still digesting a transformational merger, and the story right now is portfolio simplification: it sold Pharma Solutions to Roquette in May 2025 and agreed to sell Food Ingredients to CVC for about $4.3 billion.
• The biggest specific risk is the balance sheet: net debt sits around $6.4 billion, more than six times a year's operating income, and the whole thesis depends on divestiture proceeds bringing leverage down further.
• Watch the leverage ratio, which management has cut to about 2.6 times net-debt-to-EBITDA from 3.8 times at the end of 2024; the pace of that decline is what re-rates the stock.

Bull Case

IFF is a mature business caught mid-restructuring, and that stage is the key to reading its numbers, because the trailing profit understates what the assets earn through a normal cycle. The company makes the flavors that go into food, the fragrances that go into consumer products, and the enzymes and cultures that go into both. These are small-dollar, high-value inputs that customers design into their products and rarely switch out, which is why the underlying segments earn healthy margins even while the consolidated figure looks depressed. The filing shows the quality underneath: Health & Biosciences segment adjusted operating EBITDA reached "$594 million (26.0% of segment sales) in 2025", a margin a commodity chemicals business could never sustain. The mid-cycle operating margin on current revenue is closer to 9% than the 7.4% the trailing quarter shows, so the earnings power is real; it is just buried under one-time costs and a soft patch.

The transformation is the bull's near-term engine. Management has been simplifying the portfolio aggressively: it completed the divestiture of Pharma Solutions to Roquette in May 2025 and the Nitrocellulose business, and it agreed to sell Food Ingredients to CVC Capital Partners for about $4.3 billion, with closing targeted by late Q2 2027. Each sale does two things at once. It removes a lower-margin or non-core business, lifting the quality of what remains, and it generates cash that pays down debt. The deleveraging is already visible: net-debt-to-EBITDA fell to about 2.6 times from 3.8 times at the end of 2024, crossing below the 3.0 times threshold the company had targeted.

The re-rating case follows from the deleveraging. A company carrying six times operating income in net debt trades at a discount for the balance-sheet risk alone. As that debt comes down toward a comfortable level, the equity captures the full value of the remaining high-margin Taste and Scent and Health & Biosciences franchises without the leverage discount weighing on it. The share count has been essentially flat, so the proceeds are going to debt rather than to dilution. The bull case does not need the business to suddenly accelerate; it needs the cleaner, lower-leverage IFF that emerges from the divestiture program to be valued like the stable specialty-ingredients franchise it is rather than like a stressed balance sheet.

Bear Case

The variable with the most leverage on IFF is the cost and weight of its own debt, and the current price does not reflect how much rests on it. Net debt is about $6.4 billion, roughly 6.6 times a year's operating income, with interest covered only about 4.8 times by operating profit. That is a balance sheet built during a high-rate environment and now being unwound one asset sale at a time. The deleveraging plan is sound, but it is also the thesis: if the Food Ingredients sale to CVC slips past its late-Q2-2027 target, or closes at a lower price than the agreed $4.3 billion, the leverage stays elevated for longer, and a leveraged company in a soft demand environment is exactly where equity holders absorb the volatility. The filing is explicit that its leverage measures exist "to provide information on the extent to which we are in compliance with debt covenants", a reminder that covenants, not just optics, govern this balance sheet.

That balance-sheet exposure runs into a price that no standard method supports. At about $76 (June 27, 2026) the market values IFF at roughly 27 times its through-cycle operating income, which embeds company-wide operating growth near 18% a year for five years. Even valued on its normalized mid-cycle margins rather than the depressed trailing quarter, every family of valuation method lands below the price: asset, earnings-power, peer-multiple, and even the forward-growth methods all say the price is rich. When no family reaches the price, the market is paying for an outcome beyond what any conventional frame can justify. The implied growth also sits against a recent reality where divestitures cut sales: the Pharma Solutions exit alone carried roughly a 7% adverse impact to 2025 sales growth and about 8% to adjusted operating EBITDA growth. The company is shrinking to strengthen, which is the right move, but it makes the 18% growth the price assumes harder, not easier, to reach in the near term.

Returns on capital expose the cost of the merger that created this IFF. Return on invested capital sits near 1%, far below the cost of capital, because the balance sheet is dominated by goodwill and intangibles from the Nutrition & Biosciences combination. Return on equity is under 6%, barely above zero in economic terms. A business that earns less on its capital than the capital costs is destroying value at the margin until the divestitures and cost actions change the math. The bear case is not that IFF's products lose their place on the shelf; they will not. It is that the equity is a leveraged claim on a slow-growing, low-return asset base, priced as if the turnaround has already succeeded, while the debt clock keeps running.

Valuation

Read the price through the cycle, not the trough. Trailing earnings are depressed, so the inversion uses IFF's own through-the-cycle margins on current revenue: on that basis the market is paying about 27 times mid-cycle operating income at $76, which embeds company-wide operating growth near 18% a year for five years. That rate is within what IFF has delivered in better years, and roughly 45% of comparable companies have sustained a pace like it for five years, so the assumption is demanding but not fantastical. The harder fact is that recent growth has been negative as divestitures shrink the company, so the price assumes a reacceleration that the portfolio actions push further out before they bring it closer.

The methods we use to triangulate are unanimous in one direction: all of them land below the price. Earnings-power approaches such as capitalized free cash flow sit low because trailing free cash flow is modest against a large enterprise value. Asset and book-value methods land below the price even though book value per share is about $55, because return on equity near 6% only modestly clears the cost of equity. Peer multiples put it below as well. Even the forward-growth methods, which usually rescue a premium name, do not reach the price here. When no family reaches it, the price is a bet beyond what any standard frame supports, which for IFF means the market is paying for the post-divestiture, deleveraged business to emerge and be valued cleanly, not for the financials as they stand today.

Solvency is the load-bearing element, so it belongs at the center rather than the close. IFF carries about $6.4 billion of net debt, roughly 6.6 times a year's operating income on the company's reported basis, with interest coverage near 4.8 times. Management has cut the leverage ratio to about 2.6 times net-debt-to-EBITDA from 3.8 times at the end of 2024 using divestiture proceeds, and the agreed Food Ingredients sale to CVC for about $4.3 billion is the next major step. The downside here is not bounded by net cash, because there is none; it is bounded by whether the asset sales close on the prices and timing announced. The buyer at this price is underwriting the completion of a deleveraging program, with a high-margin specialty-ingredients franchise as the prize if it lands and a leveraged, low-return balance sheet as the exposure if it stalls.

Catalysts

The portfolio reshaping is the catalyst stream. IFF completed the divestiture of its Pharma Solutions business to Roquette on May 1, 2025, and its Nitrocellulose business, the two sales that drove the leverage ratio down to about 2.6 times net-debt-to-EBITDA from 3.8 times at the end of 2024 and pushed it below the company's 3.0 times target. The Pharma Solutions exit carried a near-term cost: full-year 2025 guidance reflected roughly a 7% adverse impact to sales growth and about 8% to adjusted operating EBITDA growth, because the divestiture closed partway through the year.

The next major event is the agreed sale of Food Ingredients to CVC Capital Partners for about $4.3 billion, with closing targeted by late Q2 2027. That transaction matters on two counts: the proceeds advance the deleveraging, and the simplification leaves a more focused Taste, Scent, and Health & Biosciences portfolio. Until it closes, the deal timing and price are the variables to watch, alongside each quarterly leverage update, because the stock's re-rating is tied more tightly to the balance sheet improving than to any single demand metric.

Peer Cohorts (Per Segment, With Filing Citations)

Taste (reported)

• SXT (Sensient Technologies Corp)
• FY2025 10-K: • Flavors & Extracts. Competition in the flavors, extracts, and flavor ingredients industries continues to have an ever-increasing global nature. Most of the Company's customers do not buy all of their flavor and flavor ingredients products from a single supplier, and the Company does not compete with a single…
• FY2025 10-K: …for the food, beverage, and personal care industries. The Company's flavor formulations are used in many of the world's best-known consumer products. Under the unified brand names of Sensient Flavors and Sensient Agricultural Ingredients, the Group is a supplier to multinational and regional companies. During 2025,…
• INGR (INGREDION INCORPORATED)
• FY2025 10-K: …Some natural high-intensity sweeteners, such as stevia, provide a sweetness or functional alternative to full-caloric sweeteners for our customers. Some food and beverage customers seek these alternatives for their reduced-calorie or sugar-free foods and beverages. Our sweetener products represented 34 percent, 35…
• FY2025 10-K: …Texture & Healthful Solutions 3,200 Food & Industrial Ingredients-LATAM 3,900 Food & Industrial Ingredients-U.S./Canada 1,300 All Other (i) 2,800 Total Ingredion 11,200 (i) All Other includes corporate employees. Workplace Safety and Employee Wellness The overall well-being and safety of our employees and customers…
• IOSP (INNOSPEC INC.)
• FY2025 10-K: …KELLER ARNOLD Keller Arnold Director /s/ DAVID F. LANDLESS David F. Landless Director /s/ LAWRENCE J. PADFIELD Lawrence J. Padfield Director /s/ LESLIE J. PARRETTE Leslie J. Parrette Director /s/ CLAUDIA POCCIA Claudia Poccia Director 98
• FY2025 10-K: …2025-01-01 2025-12-31 0001054905 iosp:QgpQuimicaGeralMember 2024-01-01 2024-06-30 0001054905 us-gaap:ConstructionInProgressMember 2025-12-31 0001054905 iosp:OtherNetIncomeExpenseMember us-gaap:NondesignatedMember us-gaap:ForeignExchangeContractMember 2025-01-01 2025-12-31 0001054905…

Food Ingredients (reported)

• INGR (INGREDION INCORPORATED)
• FY2025 10-K: …Texture & Healthful Solutions 3,200 Food & Industrial Ingredients-LATAM 3,900 Food & Industrial Ingredients-U.S./Canada 1,300 All Other (i) 2,800 Total Ingredion 11,200 (i) All Other includes corporate employees. Workplace Safety and Employee Wellness The overall well-being and safety of our employees and customers…
• FY2025 10-K: …additional information. Research and Development Our Research and Development ("R&D") organization is dedicated to driving innovation and enhancing Ingredion's competitive position within the ingredient industry. The R&D function focuses on the discovery, development, and 7 Table of Contents commercialization of…
• SXT (Sensient Technologies Corp)
• FY2025 10-K: …ingredients, and essential oils as well as flavor systems, including taste modulation, that are responsive to consumer trends and the processing needs of our food and beverage customers. These activities include the development of functional ingredient systems for foods and beverages, savory flavors, and ingredient…
• FY2025 10-K: • Flavors & Extracts. Competition in the flavors, extracts, and flavor ingredients industries continues to have an ever-increasing global nature. Most of the Company's customers do not buy all of their flavor and flavor ingredients products from a single supplier, and the Company does not compete with a single…
• NGVT (INGEVITY CORPORATION)
• FY2025 10-K: …for pre-judgment interest on its tortious interference claim as well as our motion seeking judgment as a matter of law, or a new trial in the alternative. On March 13, 2024, we appealed the verdict as well as the U.S. District Court's November 2020 dismissal of our patent infringement claims against BASF to the U.S.…
• FY2025 10-K: …• lack of access to raw materials upon which we depend would impact our ability to produce our products; • the inability to make or effectively integrate future acquisitions and other investments may negatively affect our results; • we are dependent upon third parties for the provision of certain critical operating…

Health & Biosciences (H&B) / Scent / Pharma Solutions (reported)

• SXT (Sensient Technologies Corp)
• FY2025 10-K: …positions as of December 31, 2025. As part of its commitment to quality as a competitive advantage, the Company's production facilities hold various certifications, such as those under the International Organization for Standardization (ISO) and those recognized by the Global Food Safety Initiative (GFSI), including…
• FY2025 10-K: …and nutraceutical colors, excipients, and ingredients; and ● technical colors, specialty colors, and specialty dyes and pigments. For 2025, the Company's three reportable segments were the Flavors & Extracts Group and the Color Group, which are managed on a product line basis, and the Asia Pacific Group, which is…
• INGR (INGREDION INCORPORATED)
• FY2025 10-K: …Texture & Healthful Solutions 3,200 Food & Industrial Ingredients-LATAM 3,900 Food & Industrial Ingredients-U.S./Canada 1,300 All Other (i) 2,800 Total Ingredion 11,200 (i) All Other includes corporate employees. Workplace Safety and Employee Wellness The overall well-being and safety of our employees and customers…
• FY2025 10-K: …Some natural high-intensity sweeteners, such as stevia, provide a sweetness or functional alternative to full-caloric sweeteners for our customers. Some food and beverage customers seek these alternatives for their reduced-calorie or sugar-free foods and beverages. Our sweetener products represented 34 percent, 35…
• IOSP (INNOSPEC INC.)
• FY2025 10-K: , the Company acquired QGP. This resulted in goodwill of $ 37.4 million being recognized within our Performance Chemicals segment. In the second quarter of 2024, the fair value of the acquired net assets was revised. As a result of these remeasurement period adjustments, there was an increase of $ 3.1 million to the…
• FY2025 10-K: 10-K 0001054905 0 false FY DE http://innospec.com/20251231#PresidentAndChiefExecutiveOfficerMember http://fasb.org/us-gaap/2025#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2025#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2025#OtherNonoperatingIncomeExpense…
• CBT (Cabot Corporation)
• FY2025 10-K: …improve the way we operate. The SHE & Sustainability Commitment defines several important objectives for our continuous improvement in safety, including: · Complying with all applicable regulations; · Sharing complete information about the safe handling and appropriate use of our products; · Maintaining the safety…
• FY2025 10-K: InvestmentHedgesGainLossExcludedFromEffectivenessTestingAndAmortizedToInterestExpenseMember 2024-10-01 2025-09-30 0000016040 cbt:PerformanceChemicalsMember us-gaap:EMEAMember 2023-10-01 2024-09-30 0000016040 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-10-01 2024-09-30 0000016040…
• EMN (EASTMAN CHEMICAL CO)
• FY2025 10-K: …partially offset by lower SG&A expenses. Other (Dollars in millions) 2025 2024 Sales $ 17 $ 18 Loss before interest and taxes Growth initiatives and businesses not allocated to operating segments $ (178) $ (208) Asset impairments, restructuring, and other charges, net (53) (33) Pension and other postretirement…
• FY2025 10-K: …2025-01-01 2025-12-31 0000915389 srt:LatinAmericaMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueSegmentMember emn:FibersMember 2024-01-01 2024-12-31 0000915389 srt:LatinAmericaMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueSegmentMember emn:FibersMember 2023-01-01…
• CE (CELANESE CORPORATION)
• FY2025 10-K: …additional downgrades; • volatility or changes in the price and availability of raw materials and energy, particularly changes in the demand for, supply of, and market prices of ethylene, methanol, natural gas, carbon monoxide, wood pulp, hexamethylene diamine, Polyamide 66 ("PA66"), polybutylene terephthalate,…
• FY2025 10-K: …of judicial review in consolidated Eighth Circuit petitions. The Company is currently evaluating the impact of the adoption on its financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. The new guidance requires an entity to disclose specific categories…
• HUN (Huntsman Corporation)
• FY2025 10-K: …economics. Jan Buberl , age 50, is Division President, Performance Products. Mr. Buberl was appointed to this position in August 2024. Prior to that time, Mr. Buberl served as Vice President-Americas for our Polyurethanes segment and as a director of our Chinese PO/MTBE joint venture with Sinopec since January 2019.…
• FY2025 10-K: …nature of our intellectual property rights and our business, we do not believe that any single intellectual property right (other than certain trademarks, for which we intend to maintain the applicable registrations) is material to our business. Moreover, we do not believe that the termination of intellectual…
• AVNT (AVIENT CORPORATION)
• FY2025 10-K: …No customer accounted for more than 3% of our consolidated revenues in 2025. Research and Development One of our strategic drivers is to "Amplify Innovation," and we have substantial technology and development capabilities, powered by approximately 1,100 employees serving in technical capacities, approximately 120 of…
• FY2025 10-K: …& Development and Chief Technology Officer, from July 2014 to June 2017, among other roles. Jamie A. Beggs : Senior Vice President and Chief Financial Officer, August 2020 to date. Senior Vice President and Chief Financial Officer of Hunt Consolidated, Inc. (a diversified holding company focused primarily in the…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.